Substantial dose reductions of mercaptopurine are generally required for homozygous-TPMT deficiency patients (two non-functional alleles) to avoid the development of life threatening bone marrow suppression. The gene discussed is TPMT; the disease is hyperinsulinemic hypoglycemia, familial, 4.